MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

Search

Pacira Pharmaceuticals Inc-DE

Open

SectorGezondheidszorg

20.61 3.62

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

19.52

Max

20.68

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

5.4M

Verkoop

-1.6M

180M

K/W

Sectorgemiddelde

40.766

89.037

Winstmarge

3.026

Werknemers

788

EBITDA

5.1M

34M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+53.94% upside

Dividenden

By Dow Jones

Volgende Winsten

26 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-173M

824M

Vorige openingsprijs

16.99

Vorige sluitingsprijs

20.61

Nieuwssentiment

By Acuity

63%

37%

321 / 360 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Pacira Pharmaceuticals Inc-DE Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 apr 2025, 23:45 UTC

Populaire aandelen

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

Peer Vergelijking

Prijswijziging

Pacira Pharmaceuticals Inc-DE Prognose

Koersdoel

By TipRanks

53.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.71 USD  53.94%

Hoogste 38 USD

Laagste 23 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pacira Pharmaceuticals Inc-DE - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

4

Buy

2

Hold

1

Sell

Technische score

By Trading Central

24.83 / 26.38Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

321 / 360 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
help-icon Live chat